Alexandra Snyder is a Clinical Advisor at Two River. Prior to joining Two River, Dr. Snyder was Associate Vice President of Global Clinical development at Merck, Inc, where she led Translational Oncology. She was responsible for clinical trial execution, biomarkers, companion diagnostics, and quantitative pharmacology for Oncology. Dr. Snyder featured frequently in FDA interactions about personalized medicine; her expertise in tumor genomics and neoantigens played a pivotal role in the approval of Keytruda (pembrolizumab) for tumor mutation burden-high tumors. Before joining Merck, Dr. Snyder was Translational Medicine Lead at Adaptive Biotechnologies, a biotechnology company that develops T cell receptor-based diagnostics and therapeutics. During her academic career, Dr. Snyder led clinical trials and a translational laboratory at Memorial Sloan Kettering Cancer Center (MSKCC). Dr. Snyder received her B.A. from Princeton University, her M.D. from Mount Sinai School of Medicine, Internal Medicine training at Mount Sinai Hospital and Fellowship at MSKCC. Dr. Snyder is a board-certified medical oncologist and serves as voluntary faculty at Bellevue Hospital and NYU.